8 min read · updated 2026-11-03
What the July 2026 PCAC Votes Did and Did Not Change
An advisory committee recommended six peptides for the 503A Bulks List. Four distinct regulatory states are being collapsed into one headline.
What the committee decided
At its meeting on 23 and 24 July 2026, the Pharmacy Compounding Advisory Committee recommended adding six peptides to the Section 503A Bulk Drug Substances List: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, each in free base and acetate form. It voted against recommending Emideltide, also referred to as DSIP. Seven substances were considered in total. The committee is advisory, and its votes did not change the legal status of any of them.
The vote was close, and the agency staff disagreed
BPC-157, KPV and TB-500 each passed by eight votes to six with one abstention. MOTS-c passed by seven to five with two abstentions. These are narrow margins on a divided committee. More consequential: the scientific staff at the agency had recommended against including all seven substances, citing the available information on characterisation, safety and effectiveness. The committee reached the opposite conclusion. That divergence matters, because the agency is not obliged to follow the advice of its own committee.
What the 503A Bulks List actually governs
Section 503A of the Federal Food, Drug, and Cosmetic Act governs what a state-licensed pharmacy may use when compounding a medication for an individual patient. The list, codified at 21 CFR 216.23, names bulk drug substances eligible for that use. A substance on the list has not been through premarket review, and compounded preparations do not undergo the evaluation that an approved drug application requires. The list answers a narrow question: whether a compounding pharmacy may work with a given raw substance at all.
A recommendation is not a rule
Formal addition to the list requires notice-and-comment rulemaking: a proposed rule, a public comment period, review of the comments received, and a final rule. None of that has concluded. On 30 October 2026 HHS published an interim policy saying it will not take enforcement action against licensed 503A compounding of the six recommended peptides under set conditions. That is enforcement discretion, not a listing: it is not authorisation, it adds nothing to the list, and HHS can withdraw it.
Four states that are not the same thing
Coverage of these developments routinely collapses four distinct administrative states into a single claim. Removal from Category 2, which identifies substances flagged for significant safety risk, is not placement in Category 1. Neither is addition to the 503A Bulks List. And none of the three amounts to approval of a drug by the agency. The April sequence compounded the confusion: on 15 April 2026 the agency announced, with a Federal Register notice the following day, that twelve peptides would come off the Category 2 list effective 22 April 2026. The original nominators had withdrawn their nominations that same month, after which the July meeting was scheduled and docket FDA-2025-N-6895 opened for written comment.
What changed for laboratory research material
Nothing. The compounding pathway governs pharmacies preparing medications for individual patients. Material supplied for laboratory research sits outside that pathway, and the July votes altered neither what a research supplier may offer nor how it must be labelled. What did change is the volume of public confusion. A buyer evaluating suppliers in late 2026 will encounter claims that these six peptides are now approved, legal or cleared. None of those characterisations is accurate, and a supplier making them is describing a regulatory position that does not exist.
What to verify instead
Regulatory status is not a proxy for material quality, and none of these votes says anything about the contents of a particular vial. The questions that bear on the material are unchanged. Is there a certificate tied to this specific lot rather than one representative document reused across batches? Which assays were performed, and which were not? Does the measured content correspond to the label claim? Does the lot number on the certificate match the number printed on the vial? A document that cannot survive those four questions is decorative regardless of what any committee recommended.
The six substances, and the certificates behind them
All six peptides the committee recommended appear in our catalog, each with lot-specific analytical results published rather than summarised: BPC-157, KPV, TB-500, MOTS-C, Epitalon and Semax. The certificates record what an independent laboratory measured on a specific batch: purity by HPLC-UV, identity by LC-MS, and endotoxin by LAL where that assay was performed. None of that speaks to regulatory status, and it is not intended to. It answers the separate question of what a given vial contains, which no committee vote addresses.
Sources
The answers under Frequently asked were checked against these sources on 3 November 2026.
Frequently asked
Does the July 2026 PCAC vote make BPC-157 legal to compound?
No. The committee is advisory, and formal addition to the 503A Bulks List requires notice-and-comment rulemaking, which has not concluded. Separately, since 30 October 2026 an HHS enforcement discretion policy says the agency will not act against licensed 503A compounding of BPC-157 under set conditions. That is not a listing or an approval, and it can be withdrawn.
Which peptides did the committee recommend?
BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, each in free base and acetate form. Emideltide, also referred to as DSIP, was the one substance of the seven considered that the committee recommended against.
Does removal from Category 2 mean a peptide is now Category 1?
No. Removal from Category 2, placement in Category 1, addition to the 503A Bulks List, and approval of a drug by the agency are four separate administrative states. Twelve peptides came off Category 2 effective 22 April 2026, which changed none of the other three.
Did the July votes change anything for research-use material?
No. The compounding pathway governs pharmacies preparing medications for individual patients. Material supplied for laboratory research sits outside that pathway, and neither what a research supplier may offer nor how it must be labelled was altered.
What did the October 2026 HHS policy on six peptides change?
On 28 October 2026, HHS released a draft policy. It says HHS does not intend to take enforcement action against state-licensed 503A pharmacies and physicians that compound six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. The policy covers the period while FDA finishes rulemaking on the 503A bulks list. It does not approve any of the six, does not add them to the bulks list, and does not address research-use-only material. The notice was published in the Federal Register on 30 October 2026 (Docket HHS-OASH-2026-0496), and comments are open for two weeks. Because it is a statement of enforcement discretion, it binds neither HHS nor the public and can be withdrawn. Its conditions apply to pharmacies: the bulk substance must come from a manufacturer that is registered with FDA and compliant with cGMP, and carry a valid certificate of analysis; each product may contain only one listed substance; compounding must be for a valid patient-specific prescription; and quality problems must be reported. 503B outsourcing facilities are not covered. The six are the same substances the Pharmacy Compounding Advisory Committee recommended in July 2026 (see above). The policy is meant to last until a final rule adds each peptide to the bulks list or excludes it. No date is set for that rule. The policy speaks only to compounding under section 503A. It does not change the status of laboratory research material. For research use only. Not for human or veterinary use.
See the practice, not just the principle
Every lot we release is published in full — assay, method, and measured result — and the record stays online after the lot sells out.
Open the COA library